PT  - JOURNAL ARTICLE
AU  - Cunningham, Muriel
ED  - Giugliano, Robert
TI  - Edoxaban Noninferior to Warfarin in the ENGAGE AF-TIMI 48 Trial
DP  - 2013  01
TA  - MD Conference Express
PG  - 24--25
VI  - 13
IP  - 20
4099  - http://mdc.sagepub.com/content/13/20/24.short
4100  - http://mdc.sagepub.com/content/13/20/24.full
AB  - Warfarin is widely used for stroke prevention in patients with atrial fibrillation (AF) but novel oral anticoagulants have been developed that may be just as effective [Dogliotti A et al. Clin Cardiol 2013]. Edoxaban is a direct oral factor Xa inhibitor administered once daily with a rapid onset of action. Warfarin and two doses of edoxaban were compared in the Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation — Thrombolysis in Myocardial Infarction 48 study [ENGAGE AF-TIMI 48; Giugliano RP et al. N Engl J Med 2013].